Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902689 | 0.92 | PPARA (0.60) | PPARAPPARGCYP4F2CYP4A11FFAR1 | |
| SCHEMBL11006135 | 0.89 | PPARA (0.51) | PPARAPPARGCYP4F2CYP4A11FFAR1 | |
| SCHEMBL10444982 | 0.89 | PPARA (0.61) | PPARAPPARGCYP4F2CYP4A11TDP1 | |
| SCHEMBL2354861 | 0.88 | FFAR4 (0.60) | PPARAPPARGFFAR1 | |
| SCHEMBL11624631 | 0.87 | SIRT2 (0.47) | PPARAPPARGFFAR1 | |
| SCHEMBL4128970 | 0.86 | PPARA (0.52) | PPARAPPARGFFAR1TDP1MAPK1 | |
| SCHEMBL2352290 | 0.86 | FFAR1 (0.48) | PPARAPPARGFFAR1 | |
| SCHEMBL1802183 | 0.86 | ALDH1A1 (0.56) | PPARAPPARGCYP4F2CYP4A11TDP1 | |
| SCHEMBL2349696 | 0.85 | FFAR1 (0.47) | PPARAPPARGFFAR1 | |
| SCHEMBL11006127 | 0.85 | PPARA (0.50) | PPARAPPARGCYP4F2CYP4A11FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884836-B2 | 2-substituted-5-hydroxy-4H-chromen-4-ones as novel ligands for the serotonin receptor 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-02-02 | — | — | US | disclosed |
| WO-2015116460-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-08-06 | — | — | WO | disclosed |
| US-4649141-A | HISTAMINE ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-03-10 | — | — | US | disclosed |
| US-4639519-A | 2-substituted alkylaminopyrimidones useful as H2 -antagonists and antiinflamatory agents | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-01-27 | — | — | US | disclosed |
| US-4558128-A | ANTIHISTAMINE, ANTIINFLAMMATORY AGENT | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-12-10 | — | — | US | disclosed |
| US-4539207-A | Pyrimidine compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-09-03 | — | — | US | disclosed |
| US-4496567-A | HSITAMINE H2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| US-4439435-A | PYRIMIDONE OR PYRIMID-THIONE DERIVATIVES, HISTAMINE ANTAGONIST, ANTIINFLAMMATORY | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1984-03-27 | — | — | US | disclosed |
| EP-0013071-B1 | PYRIMIDINONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-11-16 | — | — | EP | disclosed |
| US-4305945-A | Isoureas and isothioureas | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-12-15 | — | — | US | disclosed |
| EP-0003677-B1 | PYRIMIDONES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-11-11 | — | — | EP | disclosed |
| US-4234588-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-11-18 | — | — | US | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
| EP-0007232-A1 | Iso(thio)ureas, processes for their preparation and compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-01-23 | — | — | EP | disclosed |
| EP-0003677-A2 | Pyrimidones, processes for their preparation and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029399-A1 | 2-SUBSTITUTED-5-HYDROXY-4H-CHROMEN-4-ONES AS NOVEL LIGANDS FOR THE SEROTONIN RECEPTOR 2B (5-HT2B) | HTR2B, HTR3B, HTR4 | PPARA 1714/4885PPARG 1075/4885CYP4F2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.